Books on the topic 'Teeth Drugs'

United States. Congress. Senate. Committee on the Judiciary. Rogue online pharmacies: The growing problem of Internet drug trafficking : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, May 16, 2007. U.S. G.P.O., 2008.

United States. Congress. Senate. Committee on the Judiciary. Rogue online pharmacies: The growing problem of internet drug trafficking : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, May 16, 2007. U.S. G.P.O., 2008.

United States. Congress. House. Committee on the Judiciary. Subcommittee on Crime, Terrorism, and Homeland Security. Drug Enforcement Administration's regulation of medicine: Hearing before the Subcommittee on Crime, Terrorism, and Homeland Security of the Committee on the Judiciary, House of Representatives, One Hundred Tenth Congress, first session, July 12, 2007. U.S. G.P.O., 2008.

Drug Enforcement Administration's regulation of medicine: Hearing before the Subcommittee on Crime, Terrorism, and Homeland Security of the Committee on the Judiciary, House of Representatives, One Hundred Tenth Congress, first session, July 12, 2007. U.S. G.P.O., 2008.

Direct-to-consumer advertising: Marketing, education, or deception? : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, May 8, 2008. U.S. G.P.O., 2008.

FDA foreign drug inspection program: A system at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, November 1, 2007. U.S. G.P.O., 2008.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. FDA foreign drug inspection program: A system at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, November 1, 2007. U.S. G.P.O., 2008.

FDA's foreign drug inspection program: Weaknesses place Americans at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 22, 2008. U.S. G.P.O., 2008.

Online pharmacies and the problem of Internet drug abuse: Hearing before the Subcommittee on Crime, Terrorism, and Homeland Security of the Committee on the Judiciary, House of Representatives, One Hundred Tenth Congress, second session, June 24, 2008. U.S. G.P.O., 2009.

Investigations, United States Congress House Committee on Energy and Commerce Subcommittee on Oversight and. FDA's foreign drug inspection program: Weaknesses place Americans at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 22, 2008. U.S. G.P.O., 2008.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. FDA's foreign drug inspection program: Weaknesses place Americans at risk : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, April 22, 2008. U.S. G.P.O., 2008.

Prescription psychotropic drug use among children in foster care: Hearing before the Subcommittee on Income Security and Family Support of the Committee on Ways and Means, U.S. House of Representatives, One Hundred Tenth Congress, second session, May 8, 2008. U.S. G.P.O., 2009.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. The adequacy of FDA to assure the safety of the nation's drug supply: Hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, February 13, March 22, 2007. U.S. G.P.O., 2007.

FDA's role in the evaluation of Avandia's safety: Hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, June 6, 2007. U.S. G.P.O., 2008.

The Food and Drug Administration's critical mission and challenges for the future: Hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, May 1, 2007. U.S. G.P.O., 2007.

International Symposium on the Pharmacology of Thermoregulation (10th 1996 Memphis, Tenn.). Thermoregulation: Tenth International Symposium on the Pharmacology of Thermoregulation. New York Academy of Sciences, 1997.

Drug user fees: Enhancing patient access and drug safety : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining enhancing patient access and drug safety relating to prescription drug user fees, including S. 484, March 14, 2007. U.S. G.P.O., 2008.

Small market drugs, big price tags: Are drug companies exploiting people with rare disease? : hearing before the Joint Economic Committee, Congress of the United States, One Hundred Tenth Congress, second session, July 24, 2008. U.S. G.P.O., 2009.

United States. Congress. Joint Economic Committee. Small market drugs, big price tags: Are drug companies exploiting people with rare disease? : hearing before the Joint Economic Committee, Congress of the United States, One Hundred Tenth Congress, second session, July 24, 2008. U.S. G.P.O., 2009.

United States. Congress. Senate. Committee on the Judiciary. Paying off generics to prevent competition with brand name drugs: Should it be prohibited? : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, January 17, 2007. U.S. G.P.O., 2007.

United States. Congress. Joint Economic Committee. Illegal drugs: Economic impact, societal costs, policy responses : hearing before the Joint Economic Committee, Congress of the United States, One Hundred Tenth Congress, second session, June 19, 2008. U.S. G.P.O., 2009.

Illegal drugs: Economic impact, societal costs, policy responses : hearing before the Joint Economic Committee, Congress of the United States, One Hundred Tenth Congress, second session, June 19, 2008. U.S. G.P.O., 2009.

Food and Drug Administration's Critical Path Initiative: Hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Tenth Congress, first session, special hearing, June 1, 2007, Salt Lake City, Utah. U.S. G.P.O., 2008.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Assessing the safety of our nation's drug supply: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 9, 2007. U.S. G.P.O., 2008.

Assessing the safety of our nation's drug supply: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 9, 2007. U.S. G.P.O., 2008.

Protecting Consumer Access to Generic Drugs Act of 2007: Hearing before the Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, on H.R. 1902, May 2, 2007. U.S. G.P.O., 2007.

Safe and affordable biotech drugs: The need for a generic pathway : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, March 26, 2007. U.S. G.P.O., 2008.

United States. Congress. Senate. Committee on the Judiciary. Electronic prescribing of controlled substances: Addressing health care and law enforcement priorities : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, December 4, 2007. U.S. G.P.O., 2008.

U.S.-Colombia relations: Hearing before the Subcommittee on the Western Hemisphere of the Committee on Foreign Affairs, House of Representatives, One Hundred Tenth Congress, first session, April 24, 2007. U.S. G.P.O., 2007.

Breaking the methamphetamine supply chain: Meeting challenges at the border : hearing before the Committee on Finance, United States Senate, One Hundred Tenth Congress, first session, September 18, 2007. U.S. G.P.O., 2007.

Finance, United States Congress Senate Committee on. Breaking the methamphetamine supply chain: Meeting challenges at the border : hearing before the Committee on Finance, United States Senate, One Hundred Tenth Congress, first session, September 18, 2007. U.S. G.P.O., 2007.

Assessing the impact of a safe and equitable biosimilar policy in the United States: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007. U.S. G.P.O., 2008.

Symposium on New Drugs and Devices (10th 1989 Philadelphia, Pa.). Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia: Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31-November 1, 1989. Kluwer Academic Publishers, 1990.

Restoring FDA's ability to keep America's families safe: Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session, on examining the U.S. Food and Drug Administration, focusing on its ability to ensure the safety of food and the drug supply in the United States, April 24, 2008. U.S. G.P.O., 2009.

United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Restoring FDA's ability to keep America's families safe: Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, second session, on examining the U.S. Food and Drug Administration, focusing on its ability to ensure the safety of food and the drug supply in the United States, April 24, 2008. U.S. G.P.O., 2009.

United States. Congress. Senate. Committee on Commerce, Science, and Transportation. Subcommittee on Interstate Commerce, Trade, and Tourism. Policy implications of pharmaceutical importation for U.S. consumers: Hearing before the Subcommittee on Interstate Commerce, Trade, and Tourism of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Tenth Congress, first session, March 7, 2007. U.S. G.P.O., 2013.

NASPER: Why has the National All Schedules Prescription Electronic Reporting Act not been implemented? : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, October 24, 2007. U.S. G.P.O., 2008.

U.S. security assistance to Mexico: Hearing before the Subcommittee on the Western Hemisphere of the Committee on Foreign Affairs, House of Representatives, One Hundred Tenth Congress, first session, October 25, 2007. U.S. G.P.O., 2007.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Reauthorization of the Prescription Drug User Fee Act: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, April 17, 2007. U.S. G.P.O., 2008.

Reauthorization of the Prescription Drug User Fee Act: Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, April 17, 2007. U.S. G.P.O., 2008.

United States. Congress. Senate. Committee on the Judiciary. Community-based solutions to drug-related crime in rural America: Hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, second session, December 5, 2008, St. Albans, Vermont. U.S. G.P.O., 2009.

United States. Congress. Senate. Committee on the Judiciary. The rise of drug-related violent crime in rural America: Finding solutions to a growing problem : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, March 24, 2008, Rutland, Vermont. U.S. G.P.O., 2008.

The Mérida Initiative: Examining United States efforts to combat transnational criminal organizations : hearing before the Subcommittee on Border, Maritime, and Global Counterterrorism of the Committee on Homeland Security, House of Representatives, One Hundred Tenth Congress, second session, June 5, 2008. U.S. G.P.O., 2008.

Afghanistan on the brink: Where do we go from here? : hearing before the Committee on Foreign Affairs, House of Representatives, One Hundred Tenth Congress, first session, February 15, 2007. U.S. G.P.O., 2007.